A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients With Migraine
Phase of Trial: Phase III
Latest Information Update: 25 Mar 2017
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 10 Feb 2017 Status changed from not yet recruiting to recruiting.
- 07 Feb 2017 Planned initiation date changed from 1 Jan 2017 to 7 Feb 2017.
- 11 Nov 2016 New trial record